Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
The global market for CAR T-Cell Therapy was estimated to be worth US$ 1720.6 million in 2023 and is forecast to a readjusted size of US$ 13510 million by 2030 with a CAGR of 29.9% during the forecast period 2024-2030
The global top three CAR T-Cell therapy players include Novartis, Gilead Sciences, Bristol-Myers Squibb, with a total market share of more than 99%. The largest player is Gilead Sciences, with a market share of over 50%. North America is the global most important consumer market for CAR T-Cell therapy, with a market share of more than 65%. In terms of type, CD19-targeted CAR cell therapy has a market share of over 90%. In the field of application, the market share of lymphoma exceeds 90%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CAR T-Cell Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of CAR T-Cell Therapy by region & country, by Type, and by Application.
The CAR T-Cell Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR T-Cell Therapy.
麻豆原创 Segmentation
By Company
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
Autolus Therapeutics(Pipeline)
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
Bluebird Bio(Pipeline)
Cellectis(Pipeline)
Allogene Therapeutics(Pipeline)
Celyad(Pipeline)
Segment by Type:
CD19 - Targeted
BCMA - Targeted
Segment by Application
Lymphoma
Multiple Myeloma
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of CAR T-Cell Therapy manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of CAR T-Cell Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of CAR T-Cell Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 CAR T-Cell Therapy Product Introduction
1.2 Global CAR T-Cell Therapy 麻豆原创 Size Forecast
1.3 CAR T-Cell Therapy 麻豆原创 Trends & Drivers
1.3.1 CAR T-Cell Therapy Industry Trends
1.3.2 CAR T-Cell Therapy 麻豆原创 Drivers & Opportunity
1.3.3 CAR T-Cell Therapy 麻豆原创 Challenges
1.3.4 CAR T-Cell Therapy 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global CAR T-Cell Therapy Players Revenue Ranking (2023)
2.2 Global CAR T-Cell Therapy Revenue by Company (2019-2024)
2.3 Key Companies CAR T-Cell Therapy Manufacturing Base Distribution and Headquarters
2.4 Key Companies CAR T-Cell Therapy Product Offered
2.5 Key Companies Time to Begin Mass Production of CAR T-Cell Therapy
2.6 CAR T-Cell Therapy 麻豆原创 Competitive Analysis
2.6.1 CAR T-Cell Therapy 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by CAR T-Cell Therapy Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR T-Cell Therapy as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 CD19 - Targeted
3.1.2 BCMA - Targeted
3.2 Global CAR T-Cell Therapy Sales Value by Type
3.2.1 Global CAR T-Cell Therapy Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global CAR T-Cell Therapy Sales Value, by Type (2019-2030)
3.2.3 Global CAR T-Cell Therapy Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Lymphoma
4.1.2 Multiple Myeloma
4.2 Global CAR T-Cell Therapy Sales Value by Application
4.2.1 Global CAR T-Cell Therapy Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global CAR T-Cell Therapy Sales Value, by Application (2019-2030)
4.2.3 Global CAR T-Cell Therapy Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global CAR T-Cell Therapy Sales Value by Region
5.1.1 Global CAR T-Cell Therapy Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global CAR T-Cell Therapy Sales Value by Region (2019-2024)
5.1.3 Global CAR T-Cell Therapy Sales Value by Region (2025-2030)
5.1.4 Global CAR T-Cell Therapy Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America CAR T-Cell Therapy Sales Value, 2019-2030
5.2.2 North America CAR T-Cell Therapy Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe CAR T-Cell Therapy Sales Value, 2019-2030
5.3.2 Europe CAR T-Cell Therapy Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific CAR T-Cell Therapy Sales Value, 2019-2030
5.4.2 Asia Pacific CAR T-Cell Therapy Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America CAR T-Cell Therapy Sales Value, 2019-2030
5.5.2 South America CAR T-Cell Therapy Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa CAR T-Cell Therapy Sales Value, 2019-2030
5.6.2 Middle East & Africa CAR T-Cell Therapy Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions CAR T-Cell Therapy Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions CAR T-Cell Therapy Sales Value
6.3 United States
6.3.1 United States CAR T-Cell Therapy Sales Value, 2019-2030
6.3.2 United States CAR T-Cell Therapy Sales Value by Type (%), 2023 VS 2030
6.3.3 United States CAR T-Cell Therapy Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe CAR T-Cell Therapy Sales Value, 2019-2030
6.4.2 Europe CAR T-Cell Therapy Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe CAR T-Cell Therapy Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China CAR T-Cell Therapy Sales Value, 2019-2030
6.5.2 China CAR T-Cell Therapy Sales Value by Type (%), 2023 VS 2030
6.5.3 China CAR T-Cell Therapy Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan CAR T-Cell Therapy Sales Value, 2019-2030
6.6.2 Japan CAR T-Cell Therapy Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan CAR T-Cell Therapy Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea CAR T-Cell Therapy Sales Value, 2019-2030
6.7.2 South Korea CAR T-Cell Therapy Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea CAR T-Cell Therapy Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia CAR T-Cell Therapy Sales Value, 2019-2030
6.8.2 Southeast Asia CAR T-Cell Therapy Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia CAR T-Cell Therapy Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India CAR T-Cell Therapy Sales Value, 2019-2030
6.9.2 India CAR T-Cell Therapy Sales Value by Type (%), 2023 VS 2030
6.9.3 India CAR T-Cell Therapy Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Profile
7.1.2 Novartis Main Business
7.1.3 Novartis CAR T-Cell Therapy Products, Services and Solutions
7.1.4 Novartis CAR T-Cell Therapy Revenue (US$ Million) & (2019-2024)
7.1.5 Novartis Recent Developments
7.2 Gilead Sciences
7.2.1 Gilead Sciences Profile
7.2.2 Gilead Sciences Main Business
7.2.3 Gilead Sciences CAR T-Cell Therapy Products, Services and Solutions
7.2.4 Gilead Sciences CAR T-Cell Therapy Revenue (US$ Million) & (2019-2024)
7.2.5 Gilead Sciences Recent Developments
7.3 Bristol-Myers Squibb
7.3.1 Bristol-Myers Squibb Profile
7.3.2 Bristol-Myers Squibb Main Business
7.3.3 Bristol-Myers Squibb CAR T-Cell Therapy Products, Services and Solutions
7.3.4 Bristol-Myers Squibb CAR T-Cell Therapy Revenue (US$ Million) & (2019-2024)
7.3.5 J & J Recent Developments
7.4 J & J
7.4.1 J & J Profile
7.4.2 J & J Main Business
7.4.3 J & J CAR T-Cell Therapy Products, Services and Solutions
7.4.4 J & J CAR T-Cell Therapy Revenue (US$ Million) & (2019-2024)
7.4.5 J & J Recent Developments
7.5 JW Therapeutics
7.5.1 JW Therapeutics Profile
7.5.2 JW Therapeutics Main Business
7.5.3 JW Therapeutics CAR T-Cell Therapy Products, Services and Solutions
7.5.4 JW Therapeutics CAR T-Cell Therapy Revenue (US$ Million) & (2019-2024)
7.5.5 JW Therapeutics Recent Developments
7.6 FOSUNKite
7.6.1 FOSUNKite Profile
7.6.2 FOSUNKite Main Business
7.6.3 FOSUNKite CAR T-Cell Therapy Products, Services and Solutions
7.6.4 FOSUNKite CAR T-Cell Therapy Revenue (US$ Million) & (2019-2024)
7.6.5 FOSUNKite Recent Developments
7.7 CARsgen Therapeutics (Pipeline)
7.7.1 CARsgen Therapeutics (Pipeline) Profile
7.7.2 CARsgen Therapeutics (Pipeline) Main Business
7.7.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Products, Services and Solutions
7.7.4 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Revenue (US$ Million) & (2019-2024)
7.7.5 CARsgen Therapeutics (Pipeline) Recent Developments
7.8 Autolus Therapeutics(Pipeline)
7.8.1 Autolus Therapeutics(Pipeline) Profile
7.8.2 Autolus Therapeutics(Pipeline) Main Business
7.8.3 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Products, Services and Solutions
7.8.4 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Revenue (US$ Million) & (2019-2024)
7.8.5 Autolus Therapeutics(Pipeline) Recent Developments
7.9 Sorrento Therapeutics(Pipeline)
7.9.1 Sorrento Therapeutics(Pipeline) Profile
7.9.2 Sorrento Therapeutics(Pipeline) Main Business
7.9.3 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Products, Services and Solutions
7.9.4 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Revenue (US$ Million) & (2019-2024)
7.9.5 Sorrento Therapeutics(Pipeline) Recent Developments
7.10 Mustang Bio(Pipeline)
7.10.1 Mustang Bio(Pipeline) Profile
7.10.2 Mustang Bio(Pipeline) Main Business
7.10.3 Mustang Bio(Pipeline) CAR T-Cell Therapy Products, Services and Solutions
7.10.4 Mustang Bio(Pipeline) CAR T-Cell Therapy Revenue (US$ Million) & (2019-2024)
7.10.5 Mustang Bio(Pipeline) Recent Developments
7.11 Bluebird Bio(Pipeline)
7.11.1 Bluebird Bio(Pipeline) Profile
7.11.2 Bluebird Bio(Pipeline) Main Business
7.11.3 Bluebird Bio(Pipeline) CAR T-Cell Therapy Products, Services and Solutions
7.11.4 Bluebird Bio(Pipeline) CAR T-Cell Therapy Revenue (US$ Million) & (2019-2024)
7.11.5 Bluebird Bio(Pipeline) Recent Developments
7.12 Cellectis(Pipeline)
7.12.1 Cellectis(Pipeline) Profile
7.12.2 Cellectis(Pipeline) Main Business
7.12.3 Cellectis(Pipeline) CAR T-Cell Therapy Products, Services and Solutions
7.12.4 Cellectis(Pipeline) CAR T-Cell Therapy Revenue (US$ Million) & (2019-2024)
7.12.5 Cellectis(Pipeline) Recent Developments
7.13 Allogene Therapeutics(Pipeline)
7.13.1 Allogene Therapeutics(Pipeline) Profile
7.13.2 Allogene Therapeutics(Pipeline) Main Business
7.13.3 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Products, Services and Solutions
7.13.4 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Revenue (US$ Million) & (2019-2024)
7.13.5 Allogene Therapeutics(Pipeline) Recent Developments
7.14 Celyad(Pipeline)
7.14.1 Celyad(Pipeline) Profile
7.14.2 Celyad(Pipeline) Main Business
7.14.3 Celyad(Pipeline) CAR T-Cell Therapy Products, Services and Solutions
7.14.4 Celyad(Pipeline) CAR T-Cell Therapy Revenue (US$ Million) & (2019-2024)
7.14.5 Celyad(Pipeline) Recent Developments
8 Industry Chain Analysis
8.1 CAR T-Cell Therapy Industrial Chain
8.2 CAR T-Cell Therapy Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 CAR T-Cell Therapy Sales Model
8.5.2 Sales Channel
8.5.3 CAR T-Cell Therapy Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
Autolus Therapeutics(Pipeline)
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
Bluebird Bio(Pipeline)
Cellectis(Pipeline)
Allogene Therapeutics(Pipeline)
Celyad(Pipeline)
听
听
*If Applicable.